Skip to main content
. 2021 Aug 16;77(7):669–678. doi: 10.1136/thoraxjnl-2021-216882

Figure 2.

Figure 2

PDIA3 and SCGB1A1 are increased in the parenchyma in a mouse model of fibrosis. (A) Bleomycin (BLM) or PBS challenge and harvest regimen. (B) Time-dependent alterations in hydroxyproline content *p<0.05 as compared with 24-day PBS and #p<0.05 as compared with 4-day BLM samples by ANOVA; error bars±SEM (n=5–9 mice/group). (C, D) Western blot analysis and quantitation of PDIA3 normalised to the expression of β-actin in the lung lysates; *p<0.05 compared with 24-day PBS and #p<0.05 as compared with 4-day BLM samples by ANOVA (n=3 mice/group); error bars±SEM. (E and F) Representative images from confocal microscopy stained for SCGB1A1 (green), PDIA3 (red) and nucleus (blue) and quantitation of SCGB1A1 and PDIA3 in the parenchyma. Secondary antibody (without primary) staining on fibrotic mouse lungs is used as the negative control. Unpaired t-test, (n=3 mice/group); error bars±SEM. Scale bar 50 µm. (G, H) Western blot analysis and quantitation of SCGB1A1 normalised to the expression of β-actin in the lung lysates; *p<0.05 compared with 24-day PBS and #p<0.05 as compared with 4-day BLM samples by ANOVA (n=3 mice/group); error bars±SEM. (I) SCGB1A1 mRNA levels in control (n=132) and patients with IPF (n=160). ANOVA, analysis of variance; PBS, phosphate-buffered saline; PDIA3, protein disulfide isomerase A3.